In colon cancer, Xiao and colleagues reported that inhibiting the Protein kinase B (AKT) or the extracellular-signal-regulated kinase (ERK) signalling pathways downregulates expression of βIII-tubulin, indicating that βIII-tubulin could be regulated by both AKT and ERK pathways [122]. This evidence concerns the gene AKT1 and malignant colon neoplasm.